Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin

American Journal of Cardiology

Volumn 91, Issue 8, 2003, Pages 999-1002

  Abourjaily, Heather M ^a   Alsheikh Ali, Alawi A ^a   Karas, Richard H ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; THIAZOLIDINE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CHI SQUARE DISTRIBUTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DATA BASE; DEATH; DEMOGRAPHY; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG TOXICITY; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; LEUKOPENIA; LIVER FAILURE; LIVER FUNCTION TEST; LIVER NECROSIS; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PANCREAS DISEASE; PANCYTOPENIA; PATIENT CODING; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 0037446186     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00124-3     Document Type: Article

References (11)

1. National Institute for Health Care Management, Research, and Education Foundation. Prescription drug expenditures in 2001: another year of escalating costs. At http://www.nihcm.org. Accessed July 2, 2002.
2. Pasternak R., Smith S., Bairey-Merz C., Grundy S., Cleeman J., Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 40:2002;567-572.
3. Staffa J., Chang J., Green L. Cerivastatin, and reports of fatal rhabdomyolysis. N Engl J Med. 346:2002;539-540.
4. Fleck F. Bayer faces Swiss criminal probe over cerivastatin. BMJ. 324:2002;130.
5. Weaver S, Doering P. Cerivastatin and the dissemination of adverse event information. Ann Pharmacother 2002;36:1099-1103.
6. Gokmen G., Toprak A., Oktay A. Rhabdomyolysis due to cerivastatin monotherapy. Am J Med. 110:2001;742.
7. Gabay M., Lodolce A. Other reports of cerivastatin-induced rhabdomyolysis. Arch Intern Med. 161:2001;2629-2630.
8. Milionis H., Tsapoga T., Elisaf M. Another report of acute rhabdomyolysis following cerivastatin monotheapy. Arch Intern Med. 161:2001;2629-2630.
9. Alsheikh-Ali A., Abourjaily H., Karas R. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). Am J Cardiol. 89:2002;1308-1310.
10. Dart A., Jermus G., Nicholson G., d'Emden M., Hamilton-Craig I., Tallis G., Best I., West M., Sullivan D., Bracs P., Black D. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 80:1997;39-44.
11. Marz W., Wollschlager H., Klein G., Wehling M. Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). Am J Cardiol. 84:1999;7-13.